Claims

1. A compound of formula I



I

wherein

R^1 is selected from (*RS*)-[1,4]dioxan-2-yl-, (*R*)-[1,4]dioxan-2-yl-, and (*S*)-[1,4]dioxan-2-yl-;

R^2 is a) -$(CH_2)_n$-pyridin-2,3 or 4-yl, or

-$(CH_2)_n$-pyridin-2,3 or 4-yl substituted by

- lower alkyl,
- $(CH_2)_m$-O-lower alkyl,
- $(CH_2)_m$NR'R",
- $(CH_2)_m$morpholinyl,
- $(CH_2)_m$-pyrrolidin-1-yl,
- $(CH_2)_m$-piperidine-1-yl,
- $(CH_2)_m$-piperidine-1-yl substituted by hydroxy,
- $(CH_2)_m$-O-$(CH_2)_o$-CF_3,
- $(CH_2)_n$-O-$(CH_2)_m$-cycloalkyl,
- $(CH_2)_m$-O-$(CH_2)_o$-O-lower alkyl,
- $(CH_2)_m$-O-$(CH_2)_o$-2-oxo-pyrrolidin-1-yl,
- $(CH_2)_m$-O-tetrahydropyran-4-yl,
- $(CH_2)_m$-O-$(CH_2)_o$-morpholinyl,
- di-hydropyran-4-yl,
- tetra-hydropyran-4-yl
- azetidin-1-yl, or
- azetidin-1-yl substituted by halogen, lower alkoxy or hydroxy; or

b) - $(CH_2)_n$-piperidine-1-yl, or
- $(CH_2)_n$-piperidine-1-yl substituted by one or two substituents selected from
- hydroxy, - hydroxy-lower alkyl, - lower alkyl and - $(CH_2)_m$-O-lower alkyl; or

c) - $(CH_2)_n$-phenyl, or
- $(CH_2)_n$-phenyl substituted by one or two substituents selected from
- halogen, - lower alkyl, - lower alkoxy and - $(CH_2)_n$-NR'R"; or

d) - benzo[1.3]dioxol-5-yl;
- $(CH_2)_n$-morpholinyl;
- $(CH_2)_n$-tetrahydropyran-4-yl;
- $(CH_2)_n$-O-lower alkyl;
- $(CH_2)_n$-cycloalkyl;
- $(CH_2)_n$-C(O)-NR'R";
- $(CH_2)_n$-2-oxo-pyrrolidin-1-yl;
- $(CH_2)_n$NR'R";
- 2-oxa-5-aza-bicyclo[2.2.1]heptane-5-yl; or
- 1-oxa-8-aza-spiro[4.5]decane-8-yl;

R' and R" are each independently selected from lower alkyl; -$(CH_2)_o$-O-lower alkyl; cycloalkyl; lower alkyl substituted by one or more substituents selected from hydroxy and lower alkyl; -$(CH_2)_o$-O-lower alkyl substituted by one or more substituents selected from hydroxy and lower alkyl; and cycloalkyl substituted by one or more substituents selected from hydroxy and lower alkyl;

n is 0, 1, 2 or 3;
m is 0 or 1; and
o is 1 or 2;
or a pharmaceutically acceptable salt thereof.

2. A compound of formula I



I

wherein

R^1 is selected from (*RS*)-[1,4]dioxan-2-yl-, (*R*)-[1,4]dioxan-2-yl-, and (*S*)-[1,4]dioxan-2-yl-;

R^2 is a) $-(CH_2)_n$-pyridin-2,3 or 4-yl, or

$-(CH_2)_n$-pyridin-2,3 or 4-yl substituted by

- lower alkyl,
- $(CH_2)_m$-O-lower alkyl,
- $(CH_2)_m$NR'R",
- $(CH_2)_m$morpholinyl,
- $(CH_2)_m$-pyrrolidin-1-yl,
- $(CH_2)_m$-piperidine-1-yl,
- $(CH_2)_m$-piperidine-1-yl substituted by hydroxy,
- $(CH_2)_m$-O-$(CH_2)_o$-CF_3,
- $(CH_2)_n$-O-$(CH_2)_m$-cycloalkyl,
- $(CH_2)_m$-O-$(CH_2)_o$-O-lower alkyl,
- $(CH_2)_m$-O-$(CH_2)_o$-2-oxo-pyrrolidin-1-yl,
- $(CH_2)_m$-O-tetrahydropyran-4-yl,
- $(CH_2)_m$-O-$(CH_2)_o$-morpholinyl,
- di-hydropyran-4-yl,
- tetra-hydropyran-4-yl,
- azetidin-1-yl, or
- azetidin-1-yl substituted by halogen, lower alkoxy or hydroxy; or

b) - $(CH_2)_n$-piperidine-1-yl, or

- $(CH_2)_n$-piperidine-1-yl substituted by one or two substituents selected from

- hydroxy, - hydroxy-lower alkyl, - lower alkyl and - $(CH_2)_m$-O-lower alkyl; or

c) - $(CH_2)_n$-phenyl, or
- $(CH_2)_n$-phenyl substituted by one or two substituents selected from
- halogen, - lower alkyl, - lower alkoxy and - $(CH_2)_n$-NR'R"; or

d) - benzo[1.3]dioxol-5-yl;
- $(CH_2)_n$-morpholinyl;
- $(CH_2)_n$-tetrahydropyran-4-yl;
- $(CH_2)_n$-O-lower alkyl;
- $(CH_2)_n$-cycloalkyl;
- $(CH_2)_n$-C(O)-NR'R";
- $(CH_2)_n$-2-oxo-pyrrolidin-1-yl;
- $(CH_2)_n$NR'R";
- 2-oxa-5-aza-bicyclo[2.2.1]heptane-5-yl; or
- 1-oxa-8-aza-spiro[4.5]decane-8-yl;

R' and R" are each independently selected from lower alkyl; -$(CH_2)_o$-O-lower alkyl; cycloalkyl; lower alkyl substituted by hydroxy; -$(CH_2)_o$-O-lower alkyl substituted by hydroxy; and cycloalkyl substituted by hydroxy;

n is 0, 1, 2 or 3;
m is 0 or 1; and
o is 1 or 2;
or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1, wherein R^2 is substituted -$(CH_2)_n$-pyridin-4-yl.

4. The compound of claim 3, wherein the substituents are selected from the group consisting of methyl, morpholinyl, azetidin-1-yl, 3-fluoro-azetidin-1-yl, 3-methoxy-azetidin-1-yl, 3-hydroxy-azetidin-1-yl and -O-$(CH_2)_2$-morpholinyl.

5. The compound of claim 4, which is selected from:
(+)-*N*-(7-[1,4]dioxan-2-yl-4-methoxy-benzothiazol-2-yl)-2-methyl-isonicotinamide,
(+)-*N*-(7-[1,4]dioxan-2-yl-4-methoxy-benzothiazol-2-yl)-2-morpholin-4-yl-isonicotinamide,
(+)-2-azetidin-1-yl-*N*-(7-[1,4]dioxan-2-yl-4-methoxy-benzothiazol-2-yl)-isonicotinamide,
(+)-*N*-(7-[1,4]dioxan-2-yl-4-methoxy-benzothiazol-2-yl)-2-(3-fluoro-azetidin-1-yl)-isonicotinamide,
(+)-*N*-(7-[1,4]dioxan-2-yl-4-methoxy-benzothiazol-2-yl)-2-(3-methoxy-azetidin-1-yl)-isonicotinamide,
(+)-*N*-(7-[1,4]dioxan-2-yl-4-methoxy-benzothiazol-2-yl)-2-(3-hydroxy-azetidin-1-yl)-isonicotinamide and
(+)-*N*-(7-[1,4]dioxan-2-yl-4-methoxy-benzothiazol-2-yl)-2-(2-morpholin-4-yl-ethoxy)-isonicotinamide.

6. The compound of claim 1, wherein R^2 is substituted -$(CH_2)_n$-pyridin-3-yl.

7. The compound of claim 6, wherein the substituent is methoxy.

8. The compound of claim 7, wherein the compound is (+)-*N*-(7-[1,4]dioxan-2-yl-4-methoxy-benzothiazol-2-yl)-5-methoxy-nicotinamide.

9. The compound of claim 1, wherein R^2 is substituted -$(CH_2)_n$-pyridin-2-yl.

10. The compound of claim 1, wherein R^2 is unsubstituted -$(CH_2)_n$-pyridin-2, 3 or 4-yl.

11. The compound of claim 1, wherein R^2 is mono-or di-substituted -$(CH_2)_n$-phenyl.

12. The compound of claim 11, wherein the substituents are fluoro, mono- or di-methoxy or methyl.

13. The compound of claim 12, which is selected from
(+)-*N*-(7-[1,4]dioxan-2-yl-4-methoxy-benzothiazol-2-yl)-4-fluoro-benzamide,
(+)-*N*-(7-[1,4]dioxan-2-yl-4-methoxy-benzothiazol-2-yl)-4-methoxy-benzamide,
(+)-*N*-(7-[1,4]dioxan-2-yl-4-methoxy-benzothiazol-2-yl)-4-methyl-benzamide, and
(+)-*N*-(7-[1,4]dioxan-2-yl-4-methoxy-benzothiazol-2-yl)-3-methoxy-benzamide.

14. The compound of claim 1, wherein R^2 is unsubstituted -$(CH_2)_n$-phenyl.

15. The compound of claim 1, wherein R^2 is benzo[1.3]dioxol-5-yl.

16. The compound of claim 15, wherein the compound is
(+)-benzo[1,3]dioxole-5-carboxylic acid (7-[1,4]dioxan-2-yl-4-methoxy-benzothiazol-2-yl)-amide.

17. The compound of claim 1, wherein R^2 is selected from
-$(CH_2)_n$-morpholinyl, -$(CH_2)_n$-tetrahydropyran-4-yl, -$(CH_2)_n$-O-lower alkyl,
-$(CH_2)_n$-cycloalkyl, -$(CH_2)_n$-C(O)-NR'R", -$(CH_2)_n$-2-oxo-pyrrolidin-1-yl,
-$(CH_2)_n$NR'R", -2-oxa-5-aza-bicyclo[2.2.1]heptane-5-yl, and
-1-oxa-8-aza-spiro[4.5]decane-8-yl.

18. A process for preparing a compound of formula I



I

wherein

R^1 is selected from (*RS*)-[1,4]dioxan-2-yl-, (*R*)-[1,4]dioxan-2-yl-, and (*S*)-[1,4]dioxan-2-yl-;

R^2 is a) -$(CH_2)_n$-pyridin-2,3 or 4-yl, or

-$(CH_2)_n$-pyridin-2,3 or 4-yl substituted by

- lower alkyl,
- $(CH_2)_m$-O-lower alkyl,
- $(CH_2)_m$NR'R",
- $(CH_2)_m$morpholinyl,
- $(CH_2)_m$-pyrrolidin-1-yl,
- $(CH_2)_m$-piperidine-1-yl,
- $(CH_2)_m$-piperidine-1-yl substituted by hydroxy,
- $(CH_2)_m$-O-$(CH_2)_o$-CF_3,
- $(CH_2)_n$-O-$(CH_2)_m$-cycloalkyl,
- $(CH_2)_m$-O-$(CH_2)_o$-O-lower alkyl,
- $(CH_2)_m$-O-$(CH_2)_o$-2-oxo-pyrrolidin-1-yl,
- $(CH_2)_m$-O-tetrahydropyran-4-yl,
- $(CH_2)_m$-O-$(CH_2)_o$-morpholinyl,
- di-hydropyran-4-yl,
- tetra-hydropyran-4-yl
- azetidin-1-yl, or
- azetidin-1-yl substituted by halogen, lower alkoxy or hydroxy; or

b) - $(CH_2)_n$-piperidine-1-yl, or

- $(CH_2)_n$-piperidine-1-yl substituted by one or two substituents selected from
  - hydroxy, - hydroxy-lower alkyl, - lower alkyl and - $(CH_2)_m$-O-lower alkyl; or

c) - $(CH_2)_n$-phenyl, or

- $(CH_2)_n$-phenyl substituted by one or two substituents selected from
  - halogen, - lower alkyl, - lower alkoxy and - $(CH_2)_n$-NR'R"; or

d) - benzo[1.3]dioxol-5-yl;
- $(CH_2)_n$-morpholinyl;
- $(CH_2)_n$-tetrahydropyran-4-yl;
- $(CH_2)_n$-O-lower alkyl;
- $(CH_2)_n$-cycloalkyl;
- $(CH_2)_n$-C(O)-NR'R";
- $(CH_2)_n$-2-oxo-pyrrolidin-1-yl;
- $(CH_2)_n$NR'R";
- 2-oxa-5-aza-bicyclo[2.2.1]heptane-5-yl; or
- 1-oxa-8-aza-spiro[4.5]decane-8-yl;

R' and R" are each independently selected from lower alkyl; -$(CH_2)_o$-O-lower alkyl; cycloalkyl; lower alkyl substituted by one or more substituents selected from hydroxy and lower alkyl; -$(CH_2)_o$-O-lower alkyl substituted by one or more substituents selected from hydroxy and lower alkyl; and cycloalkyl substituted by one or more substituents selected from hydroxy and lower alkyl;

n is 0, 1, 2 or 3;
m is 0 or 1; and
o is 1 or 2;
or a pharmaceutically acceptable salt thereof,
which process comprises

a) reacting a compound of formula 5



(5)

with a compound of formula

$ClC(O)R^2$ / base (6)

or with a compound of formula

$$HOC(O)R^2 \ / \ HATU \ /base \quad (7)$$

to produce a compound of formula I



I

wherein R^1 is as defined above,

19. A process for preparing a compound of formula I



I

wherein

R^1 is selected from (*RS*)-[1,4]dioxan-2-yl-, (*R*)-[1,4]dioxan-2-yl-, and (*S*)-[1,4]dioxan-2-yl-;

R^2 is a) $-(CH_2)_n$-pyridin-2,3 or 4-yl, or

$-(CH_2)_n$-pyridin-2,3 or 4-yl substituted by

- lower alkyl,
- $(CH_2)_m$-O-lower alkyl,
- $(CH_2)_m$NR'R",
- $(CH_2)_m$morpholinyl,
- $(CH_2)_m$-pyrrolidin-1-yl,
- $(CH_2)_m$-piperidine-1-yl,
- $(CH_2)_m$-piperidine-1-yl substituted by hydroxy,
- $(CH_2)_m$-O-$(CH_2)_o$-CF_3,
- $(CH_2)_n$-O-$(CH_2)_m$-cycloalkyl,
- $(CH_2)_m$-O-$(CH_2)_o$-O-lower alkyl,
- $(CH_2)_m$-O-$(CH_2)_o$-2-oxo-pyrrolidin-1-yl,

- $(CH_2)_m$-O-tetrahydropyran-4-yl,
- $(CH_2)_m$-O-$(CH_2)_o$-morpholinyl,
- di-hydropyran-4-yl,
- tetra-hydropyran-4-yl
- azetidin-1-yl, or
- azetidin-1-yl substituted by halogen, lower alkoxy or hydroxy; or

b) - $(CH_2)_n$-piperidine-1-yl, or
- $(CH_2)_n$-piperidine-1-yl substituted by one or two substituents selected from
  - hydroxy, - hydroxy-lower alkyl, - lower alkyl and - $(CH_2)_m$-O-lower alkyl; or

c) - $(CH_2)_n$-phenyl, or
- $(CH_2)_n$-phenyl substituted by one or two substituents selected from
  - halogen, - lower alkyl, - lower alkoxy and - $(CH_2)_n$-NR'R"; or

d) - benzo[1.3]dioxol-5-yl;
- $(CH_2)_n$-morpholinyl;
- $(CH_2)_n$-tetrahydropyran-4-yl;
- $(CH_2)_n$-O-lower alkyl;
- $(CH_2)_n$-cycloalkyl;
- $(CH_2)_n$-C(O)-NR'R";
- $(CH_2)_n$-2-oxo-pyrrolidin-1-yl;
- $(CH_2)_n$NR'R";
- 2-oxa-5-aza-bicyclo[2.2.1]heptane-5-yl; or
- 1-oxa-8-aza-spiro[4.5]decane-8-yl;

R' and R" are each independently selected from lower alkyl; -$(CH_2)_o$-O-lower alkyl; cycloalkyl; lower alkyl substituted by one or more substituents selected from hydroxy and lower alkyl; -$(CH_2)_o$-O-lower alkyl substituted by one or more substituents selected from

hydroxy and lower alkyl; and cycloalkyl substituted by one or more substituents selected from hydroxy and lower alkyl;

n is 0, 1, 2 or 3;

m is 0 or 1; and

o is 1 or 2;

or a pharmaceutically acceptable salt thereof, which process comprises reacting a compound of formula 8



(8)

with a compound of formula

HR^2 / base (9)

to produce a compound of formula I



I

wherein R^1 is as defined above.

20. A process for preparing a compound of formula I



I

wherein

R^1 is selected from (*RS*)-[1,4]dioxan-2-yl-, (*R*)-[1,4]dioxan-2-yl-, and (*S*)-[1,4]dioxan-2-yl-;

R^2 is a) -$(CH_2)_n$-pyridin-2,3 or 4-yl, or

-$(CH_2)_n$-pyridin-2,3 or 4-yl substituted by

- lower alkyl,
- $(CH_2)_m$-O-lower alkyl,
- $(CH_2)_m$NR'R",
- $(CH_2)_m$morpholinyl,
- $(CH_2)_m$-pyrrolidin-1-yl,
- $(CH_2)_m$-piperidine-1-yl,
- $(CH_2)_m$-piperidine-1-yl substituted by hydroxy,
- $(CH_2)_m$-O-$(CH_2)_o$-CF_3,
- $(CH_2)_n$-O-$(CH_2)_m$-cycloalkyl,
- $(CH_2)_m$-O-$(CH_2)_o$-O-lower alkyl,
- $(CH_2)_m$-O-$(CH_2)_o$-2-oxo-pyrrolidin-1-yl,
- $(CH_2)_m$-O-tetrahydropyran-4-yl,
- $(CH_2)_m$-O-$(CH_2)_o$-morpholinyl,
- di-hydropyran-4-yl,
- tetra-hydropyran-4-yl
- azetidin-1-yl, or
- azetidin-1-yl substituted by halogen, lower alkoxy or hydroxy; or

b) - $(CH_2)_n$-piperidine-1-yl, or

- $(CH_2)_n$-piperidine-1-yl substituted by one or two substituents selected from
  - hydroxy, - hydroxy-lower alkyl, - lower alkyl and - $(CH_2)_m$-O-lower alkyl; or

c) - $(CH_2)_n$-phenyl, or

- $(CH_2)_n$-phenyl substituted by one or two substituents selected from
  - halogen, - lower alkyl, - lower alkoxy and - $(CH_2)_n$-NR'R"; or

d) - benzo[1.3]dioxol-5-yl;

- $(CH_2)_n$-morpholinyl;

- $(CH_2)_n$-tetrahydropyran-4-yl;
- $(CH_2)_n$-O-lower alkyl;
- $(CH_2)_n$-cycloalkyl;
- $(CH_2)_n$-C(O)-NR'R";
- $(CH_2)_n$-2-oxo-pyrrolidin-1-yl;
- $(CH_2)_n$NR'R";
- 2-oxa-5-aza-bicyclo[2.2.1]heptane-5-yl; or
- 1-oxa-8-aza-spiro[4.5]decane-8-yl;

R' and R" are each independently selected from lower alkyl; -$(CH_2)_o$-O-lower alkyl; cycloalkyl; lower alkyl substituted by one or more substituents selected from hydroxy and lower alkyl; -$(CH_2)_o$-O-lower alkyl substituted by one or more substituents selected from hydroxy and lower alkyl; and cycloalkyl substituted by one or more substituents selected from hydroxy or lower alkyl;

n is 0, 1, 2 or 3;
m is 0 or 1; and
o is 1 or 2;

or a pharmaceutically acceptable salt thereof, which process comprises separating a racemic compound of formula I into its (*R*)- and (*S*)-enantiomers.

21. The process of claim 18 further comprising converting the compound obtained into its pharmaceutically acceptable salt..

22. The process of claim 19 further comprising converting the compound obtained into its pharmaceutically acceptable salt.

23. The process of claim 20 further comprising converting the compound obtained into its pharmaceutically acceptable salt.

24. A pharmaceutical composition which comprises a compound of formula I



wherein

R^1 is selected from (*RS*)-[1,4]dioxan-2-yl-, (*R*)-[1,4]dioxan-2-yl-, and (*S*)-[1,4]dioxan-2-yl-;

R^2 is a) -$(CH_2)_n$-pyridin-2,3 or 4-yl, or

-$(CH_2)_n$-pyridin-2,3 or 4-yl substituted by

- lower alkyl,
- $(CH_2)_m$-O-lower alkyl,
- $(CH_2)_m$NR'R",
- $(CH_2)_m$morpholinyl,
- $(CH_2)_m$-pyrrolidin-1-yl,
- $(CH_2)_m$-piperidine-1-yl,
- $(CH_2)_m$-piperidine-1-yl substituted by hydroxy,
- $(CH_2)_m$-O-$(CH_2)_o$-CF_3,
- $(CH_2)_n$-O-$(CH_2)_m$-cycloalkyl,
- $(CH_2)_m$-O-$(CH_2)_o$-O-lower alkyl,
- $(CH_2)_m$-O-$(CH_2)_o$-2-oxo-pyrrolidin-1-yl,
- $(CH_2)_m$-O-tetrahydropyran-4-yl,
- $(CH_2)_m$-O-$(CH_2)_o$-morpholinyl,
- di-hydropyran-4-yl,
- tetra-hydropyran-4-yl
- azetidin-1-yl, or
- azetidin-1-yl substituted by halogen, lower alkoxy or hydroxy; or

b) - $(CH_2)_n$-piperidine-1-yl, or

- $(CH_2)_n$-piperidine-1-yl substituted by one or two substituents selected from

- hydroxy, - hydroxy-lower alkyl, - lower alkyl and - $(CH_2)_m$-O-lower alkyl; or

c) - $(CH_2)_n$-phenyl, or
- $(CH_2)_n$-phenyl substituted by one or two substituents selected from
- halogen, - lower alkyl, - lower alkoxy and - $(CH_2)_n$-NR'R"; or

d) - benzo[1.3]dioxol-5-yl;
- $(CH_2)_n$-morpholinyl;
- $(CH_2)_n$-tetrahydropyran-4-yl;
- $(CH_2)_n$-O-lower alkyl;
- $(CH_2)_n$-cycloalkyl;
- $(CH_2)_n$-C(O)-NR'R";
- $(CH_2)_n$-2-oxo-pyrrolidin-1-yl;
- $(CH_2)_n$NR'R";
- 2-oxa-5-aza-bicyclo[2.2.1]heptane-5-yl; or
- 1-oxa-8-aza-spiro[4.5]decane-8-yl;

R' and R" are each independently selected from lower alkyl; -$(CH_2)_o$-O-lower alkyl; cycloalkyl; lower alkyl substituted by one or more substituents selected from hydroxy and lower alkyl; -$(CH_2)_o$-O-lower alkyl substituted by one or more substituents selected from hydroxy and lower alkyl, and cycloalkyl substituted by one or more substituents selected from hydroxy or lower alkyl;

n is 0, 1, 2 or 3;
m is 0 or 1; and
o is 1 or 2;

or a pharmaceutically acceptable salt thereof,
and a pharmaceutically acceptable excipient.

25. A method of treating a disease based on adenosine A_{2a} receptor activity comprising administering to a patient in need of such treatment a therapeutically effective amount of at least one compound of formula I



I

wherein

R^1 is selected from (*RS*)-[1,4]dioxan-2-yl-, (*R*)-[1,4]dioxan-2-yl-, and (*S*)-[1,4]dioxan-2-yl-;

R^2 is a) -$(CH_2)_n$-pyridin-2,3 or 4-yl, or

-$(CH_2)_n$-pyridin-2,3 or 4-yl substituted by

- lower alkyl,
- $(CH_2)_m$-O-lower alkyl,
- $(CH_2)_m$NR'R",
- $(CH_2)_m$morpholinyl,
- $(CH_2)_m$-pyrrolidin-1-yl,
- $(CH_2)_m$-piperidine-1-yl,
- $(CH_2)_m$-piperidine-1-yl substituted by hydroxy,
- $(CH_2)_m$-O-$(CH_2)_o$-CF_3,
- $(CH_2)_n$-O-$(CH_2)_m$-cycloalkyl,
- $(CH_2)_m$-O-$(CH_2)_o$-O-lower alkyl,
- $(CH_2)_m$-O-$(CH_2)_o$-2-oxo-pyrrolidin-1-yl,
- $(CH_2)_m$-O-tetrahydropyran-4-yl,
- $(CH_2)_m$-O-$(CH_2)_o$-morpholinyl,
- di-hydropyran-4-yl,
- tetra-hydropyran-4-yl
- azetidin-1-yl, or
- azetidin-1-yl substituted by halogen, lower alkoxy or hydroxy; or

b) - $(CH_2)_n$-piperidine-1-yl, or
- $(CH_2)_n$-piperidine-1-yl substituted by one or two substituents selected from
- hydroxy, - hydroxy-lower alkyl, - lower alkyl and - $(CH_2)_m$-O-lower alkyl; or

c) - $(CH_2)_n$-phenyl, or
- $(CH_2)_n$-phenyl substituted by one or two substituents selected from
- halogen, - lower alkyl, - lower alkoxy and - $(CH_2)_n$-NR'R"; or

d) - benzo[1.3]dioxol-5-yl;
- $(CH_2)_n$-morpholinyl;
- $(CH_2)_n$-tetrahydropyran-4-yl;
- $(CH_2)_n$-O-lower alkyl;
- $(CH_2)_n$-cycloalkyl;
- $(CH_2)_n$-C(O)-NR'R";
- $(CH_2)_n$-2-oxo-pyrrolidin-1-yl;
- $(CH_2)_n$NR'R";
- 2-oxa-5-aza-bicyclo[2.2.1]heptane-5-yl; or
- 1-oxa-8-aza-spiro[4.5]decane-8-yl;

R' and R" are each independently selected from lower alkyl; -$(CH_2)_o$-O-lower alkyl; cycloalkyl; lower alkyl substituted by one or more substituents selected from hydroxy and lower alkyl; -$(CH_2)_o$-O-lower alkyl substituted by one or more substituents selected from hydroxy and lower alkyl; and cycloalkyl substituted by one or more substituents selected from hydroxy or lower alkyl;

n is 0, 1, 2 or 3;
m is 0 or 1; and
o is 1 or 2;
or a pharmaceutically acceptable salt thereof.